Suprascapular and Axillary Blocks Versus Interscalene Block for Shoulder Surgery (PASS)

May 29, 2018 updated by: University Health Network, Toronto

Novel Combination of Suprascapular & Axillary Nerve Blocks Versus Conventional Interscalene Brachial Plexus Block for Pain Relief Following Shoulder Surgery: A Multi-centre Randomized, Patient & Assessor Blinded, Non-inferiority Trial

The purpose of this study is to determine whether the combination of suprascapular and axillary nerve blocks is non-inferior to the conventional interscalene block (ISB) in providing pain relief during the first postoperative day to adult healthy patients (age > 18) undergoing ambulatory shoulder surgery.

Study Overview

Status

Completed

Conditions

Detailed Description

Study Hypothesis:The pain relief provided by a combination of suprascapular and axillary nerve blocks is non-inferior to that produced by the conventional interscalene block during the first 24hours postoperatively in adult patients undergoing ambulatory shoulder surgery.

Intervention and Comparator: Consented patients will be randomized to receive either pre-operative ISB (plus sham SAB with subcutaneous saline), or SAB (plus sham ISB). Both groups will receive general anesthesia for surgery.

Primary Aim: To demonstrate non-inferiority of pain relief produced by the combination treatment compared to the conventional treatment by comparing the area under the curve of the postoperative pain scores plot over time during the first 24 hours postoperatively.

Secondary Aims: There are four secondary aims, covering efficacy (analgesia) and safety: rest pain, quality of recovery, safety, other pain relief indicators.

Design There will be a multi-centre, prospective, randomized, patient and assessor blinded, two-arm, parallel-group, 1:1 allocation ratio, placebo-controlled, non-inferiority clinical trial comparing the effect of SAB treatment to conventional ISB treatment on pain relief during the first postoperative 24 hours in patients undergoing ambulatory shoulder surgery under general anesthesia.

Methods Study participants

The target population will be adult patients (age > 18) presenting for outpatient (same day surgery) unilateral arthroscopic or open shoulder surgery. Eligible surgical procedures are:

  • Shoulder arthroscopy
  • Shoulder instability procedures

    1. Superior labrum anterior posterior repair (SLAP)
    2. Rotator cuff repair
    3. Bankart repair
  • Acromioplasty

Study centres The trial will be conducted at the two academic medical centres in Toronto where ambulatory shoulder surgery is routinely performed: Toronto Western Hospital (TWH),and Women's College Hospital (WCH).

Preoperative management Unless allergic, all patients will receive acetaminophen 1 gr and celecoxib 400 mg orally with sips of water one hour prior to surgery. All blocks will be performed in the block room one hour before surgery.

Suprascapular and axillary nerve blocks (SAB group) Patients allocated to the suprascapular and axillary nerve block combination (SAB group) will receive these blocks in the sitting position. The shoulder will be in the neutral position but rotated 45 degrees inward and the elbow flexed at 90 degrees while the hand rests on the knees. The suprascapular nerve will be blocked as it branches from the superior trunk.78After sterile skin preparation with chlorhexidine, a linear array transducer (6-13 MHz, Sonosite M-Turbo) probe protected by a 3M Tegaderm® dressing or a sterile sheath is placed in the transverse plane to visualize C5 and C6 roots in the interscalene groove. These roots are then traced distally to where they coalesce to form the superior trunk. The suprascapular nerve is then identified and as it emerges from the superior trunk, under the deep cervical fascia and superficial to the middle scalene muscle. After infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle (B. Braun Medical Inc., Bethlehem, PA, USA) is inserted in line with the probe in a lateral-to-medial orientation towards the nerve. Local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration for blood to achieve circumferential spread around the nerve.

The axillary nerve block will be performed next in the posterior aspect of the operative arm. The US transducer is placed in the longitudinal plane, parallel to the long axis of the humerus shaft and approximately 2cm below the postero-lateral part of the acromion on the posterior aspect of the arm. (Figure 1) The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, the 22G needle is inserted in line with the probe in a caudad orientation towards the bundle. Local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.

Finally, to maintain patient blinding, sham ISB block will be performed in the semi-sitting position using a 25G needle to inject 1 mL of lidocaine 1% subcutaneously.

Interscalene block (ISB group) Local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots. Subsequently, patients will receive sham SAB performed in the sitting position using a 25G needle to inject 1 mL of lidocaine 1% subcutaneously.

Block assessment Assessment of sensory block onset to confirm block success is done by the research assistant doing the blocks every 5 minutes, for 30 minutes, with a blunt 22G needle applied to skin, by comparing to the contralateral upper extremity.

General anesthesia All patients will receive a standardized general anesthetic.

Postoperative management Discharged patients will receive a prescription for Tylenol #3® as needed, or Percocet® if intolerant to codeine.

Two-week follow-up A study follow-up phone call will be arranged to specifically assess any potential block-related neurologic symptoms such as pain, paresthesia, dysesthesia, sensory loss, motor power weakness. Patients found to have such symptoms will be offered a referral to the chronic pain clinic at TWH for assessment and management.

Data collection The study coordinators of the participating sites will use a paper-based case report form (CRF) prepared by the principal investigator for documentation of outcome results. Subject confidentiality will be maintained by using a study ID (not related to name, or date of birth) on all CRFs.

Sample Size Investigators aim to enroll a total of 65 patients per group, or a total of 130 patients. Based on the annual number of shoulder surgeries performed at each centre, the researchers plan to recruit 45 patients at TWH, and another 85 patients at WCH.

Source Data Verification: Patient Electronic Record

Quality Assurance & Data Checks: N/A

Study Type

Interventional

Enrollment (Actual)

130

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5T2S8
        • Toronto Western Hopspital
      • Toronto, Ontario, Canada, M5S 1B2
        • Women's College Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Consented, English-speaking, adult patients (age > 18)
  • American Society of Anesthesiologists (ASA) classification I-III
  • BMI ≤ 30 kg/m2

Exclusion Criteria:

  • Total shoulder arthroplasty or clavicular surgery (ISB does not provide sufficient pain relief)
  • Known broncho-pulmonary or phrenic pathology compromising respiratory function
  • Contra-indication to nerve blocks e.g., infection, bleeding diathesis, allergy to local anesthetics
  • Existing chronic pain disorders or history of use of ≥ 30mg oxycodone or equivalent per day
  • Pre-existing neurological deficits or peripheral neuropathy involving the operative upper extremity
  • Contraindication to any component of multi-modal analgesia (acetaminophen, non-steroidal anti-inflammatory medications, oral opioid analgesics)
  • Pregnancy or any significant psychiatric conditions that may affect patient assessment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Suprascapular & axillary blocks
Suprascapular and axillary blocks.
After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
Other Names:
  • Suprascapular and axillary blocks
Active Comparator: Interscalene block
Interscalene block.
After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative pain severity
Time Frame: 1st post-operative 24 hours
Numeric rating scale (NRS) scores will be evaluated by blinded study coordinators who are not involved in patient care.
1st post-operative 24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rest pain at additional time points
Time Frame: 0, 6, 12, 18, and 24 hours postoperatively
0, 6, 12, 18, and 24 hours postoperatively
Quality of Recovery (QoR)
Time Frame: 24 hours
The impact of surgical and anesthetic interventions on perioperative quality of life and ability to resume routine life activities will be assessed using the Quality of Recovery (QoR) tool. The QoR-15 scale is a patient-based outcome measure in the form of a 15-item validated questionnaire.
24 hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hemodynamic side effect
Time Frame: 24 hours
Hemodynamic side effects, defined as occurrence of bradycardia or hypo-tension.
24 hours
Block success
Time Frame: 24 hours
Block success is defined as complete sensory block over the deltoid.
24 hours
Procedural complications
Time Frame: during or just after block.
Procedural complications are defined as occurrence of intravascular injection, local anesthetic systemic toxicity, hematoma, pneumothorax, epidural spread, and Horner's syndrome
during or just after block.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Faraj Abdallah, MD, St. Michael's Hospital, University of Toronto
  • Principal Investigator: Richard Brull, MD, Women's College Hospital, University of Toronto

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2015

Primary Completion (Actual)

January 1, 2018

Study Completion (Actual)

January 1, 2018

Study Registration Dates

First Submitted

July 20, 2015

First Submitted That Met QC Criteria

August 6, 2015

First Posted (Estimate)

August 7, 2015

Study Record Updates

Last Update Posted (Actual)

May 31, 2018

Last Update Submitted That Met QC Criteria

May 29, 2018

Last Verified

March 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • REB14-8557-A

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

publication

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Shoulder Pain

Clinical Trials on Suprascapular & axillary blocks

Subscribe